Increases in serum MDC levels are greater in severe AD patients than in moderate or mild AD cohorts, decrease after treatment, and significantly correlates with the Scoring AD (SCORAD) index [25] and CCL18 [21]. This evidence concerns the gene CCL18 and Alzheimer disease.